1-17 of 17
Susan Halabi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Susan Halabi, Siyuan Guo, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Donald P. McDonnell, John D. Norris, Changxue Lu, Jun Luo, Andrew J. Armstrong
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1152–1159.
https://doi.org/10.1158/1078-0432.CCR-23-3017
Published: 15 March 2024
View article titled, The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
Open the PDF for The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide in another window
Includes: Supplementary data
Journal Articles

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1929–1937.
https://doi.org/10.1158/1078-0432.CCR-22-3233
Published: 15 May 2023
View article titled, PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
Open the PDF for PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Andrew B. Nixon, Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, Herbert I. Hurwitz, Phillip G. Febbo, Brian I. Rini, Himisha Beltran, Eric J. Small, Michael J. Morris, Daniel J. George
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2771–2778.
https://doi.org/10.1158/1078-0432.CCR-21-2386
Published: 01 July 2022
View article titled, Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Open the PDF for Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance) in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Landon C. Brown, Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Ethan S. Barnett, Emily A. Carbone, Jimmy L. Zhao, Patrick Healy, Monika Anand, Audrey Gill, Adam Jendrisak, William R. Berry, Santosh Gupta, Simon G. Gregory, Richard Wenstrup, Emmanuel S. Antonarakis, Daniel J. George, Howard I. Scher, Andrew J. Armstrong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 4077–4088.
https://doi.org/10.1158/1078-0432.CCR-20-3471
Published: 15 July 2021
View article titled, Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Open the PDF for Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide in another window
Includes: Supplementary data
Journal Articles

Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma

Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian K. Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa M. Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, Susan Halabi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3503.
https://doi.org/10.1158/1078-0432.CCR-21-1636
Published: 15 June 2021
View article titled, Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma
Open the PDF for Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma in another window
Journal Articles

Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian K. Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa M. Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, Susan Halabi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3317–3328.
https://doi.org/10.1158/1078-0432.CCR-20-4504
Published: 15 June 2021
View article titled, Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
Open the PDF for Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Bert H. O’Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, Yukihide Momozawa, Michiaki Kubo, Donna Niedzwiecki, Howard S. Hochster, Heinz-Josef Lenz, James N. Atkins, Hope S. Rugo, Susan Halabi, William Kevin Kelly, Howard L. McLeod, Federico Innocenti, Mark J. Ratain, Alan P. Venook, Kouros Owzar, Deanna L. Kroetz
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4734–4744.
https://doi.org/10.1158/1078-0432.CCR-17-1523
Published: 01 October 2018
View article titled, Identification of a Genomic Region between <em>SLC29A1</em> and <em>HSP90AB1</em> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Open the PDF for Identification of a Genomic Region between <em>SLC29A1</em> and <em>HSP90AB1</em> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) in another window
Includes: Supplementary data
Journal Articles

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy

Himisha Beltran, Alexander W. Wyatt, Edmund C. Chedgy, Adam Donoghue, Matti Annala, Evan W. Warner, Kevin Beja, Michael Sigouros, Fan Mo, Ladan Fazli, Colin C. Collins, James Eastham, Michael Morris, Mary-Ellen Taplin, Andrea Sboner, Susan Halabi, Martin E. Gleave
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (22): 6802–6811.
https://doi.org/10.1158/1078-0432.CCR-17-1034
Published: 14 November 2017
View article titled, Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Open the PDF for Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy in another window
Includes: Supplementary data
Journal Articles

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Daniel L. Hertz, Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William Kevin Kelly, Jai Patel, Susan Halabi, Yoichi Furukawa, Heather E. Wheeler, Alexander B. Sibley, Cameron Lassiter, Lois Weisman, Dorothy Watson, Stefanie D. Krens, Flora Mulkey, Cynthia L. Renn, Eric J. Small, Phillip G. Febbo, Ivo Shterev, Deanna L. Kroetz, Paula N. Friedman, John F. Mahoney, Michael A. Carducci, Michael J. Kelley, Yusuke Nakamura, Michiaki Kubo, Susan G. Dorsey, M. Eileen Dolan, Michael J. Morris, Mark J. Ratain, Howard L. McLeod
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4890–4900.
https://doi.org/10.1158/1078-0432.CCR-15-2823
Published: 02 October 2016
View article titled, Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <em>VAC14</em> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Open the PDF for Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <em>VAC14</em> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy in another window
Includes: Supplementary data
Journal Articles

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer

Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, S. Lindsay Davis, Ting Wang, Roula Albadine, Luciana Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Phillip G. Febbo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3057–3066.
https://doi.org/10.1158/1078-0432.CCR-10-0124
Published: 31 May 2010
View article titled, A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Open the PDF for A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study

Charles J. Ryan, Susan Halabi, San-San Ou, Nicholas J. Vogelzang, Philip Kantoff, Eric J. Small, for the Cancer and Leukemia Group B
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2030–2037.
https://doi.org/10.1158/1078-0432.CCR-06-2344
Published: 02 April 2007
View article titled, Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study
Open the PDF for Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study in another window
Journal Articles

Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee

Eric J. Small, Susan Halabi, Phillip Kantoff, Anthony D'Amico, Walter Stadler, W. Kevin Kelley, James Mohler, Dean Bajorin, Nicholas J. Vogelzang
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3596s–3600s.
https://doi.org/10.1158/1078-0432.CCR-06-9005
Published: 01 June 2006
View article titled, Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee
Open the PDF for Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee in another window
Journal Articles

Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study

Robert W. Ross, Susan Halabi, San-San Ou, Barur R. Rajeshkumar, Bruce A. Woda, Nicholas J. Vogelzang, Eric J. Small, Mary-Ellen Taplin, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (22): 8109–8113.
https://doi.org/10.1158/1078-0432.CCR-05-1250
Published: 18 November 2005
View article titled, Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study
Open the PDF for Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study in another window
Journal Articles

The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480

Daniel J. George, Susan Halabi, Timothy F. Shepard, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (5): 1815–1820.
https://doi.org/10.1158/1078-0432.CCR-04-1560
Published: 08 March 2005
View article titled, The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480
Open the PDF for The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 in another window
Journal Articles

Cancer and Leukemia Group B 90206: A Randomized Phase III Trial of Interferon-α or Interferon-α Plus Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Metastatic Renal Cell Carcinoma

Brian I. Rini, Susan Halabi, John Taylor, Eric J. Small, Richard L. Schilsky, for the Cancer Leukemia Group B
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (8): 2584–2586.
https://doi.org/10.1158/1078-0432.CCR-03-0605
Published: 20 April 2004
View article titled, Cancer and Leukemia Group B 90206: <subtitle>A Randomized Phase III Trial of Interferon-α or Interferon-α Plus Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Metastatic Renal Cell Carcinoma</subtitle>
Open the PDF for Cancer and Leukemia Group B 90206: <subtitle>A Randomized Phase III Trial of Interferon-α or Interferon-α Plus Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Metastatic Renal Cell Carcinoma</subtitle> in another window
Journal Articles

Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480

Daniel J. George, Susan Halabi, Timothy F. Shepard, Nicholas J. Vogelzang, Daniel F. Hayes, Eric J. Small, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1932–1936.
Published: 01 July 2001
View article titled, Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480
Open the PDF for Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480 in another window
Journal Articles

Phase I Clinical Study of Fish Oil Fatty Acid Capsules for Patients with Cancer Cachexia: Cancer and Leukemia Group B Study 9473

C. Patrick Burns, Susan Halabi, Gerald H. Clamon, Vera Hars, Brett A. Wagner, Raymond J. Hohl, Eric Lester, Jeffrey J. Kirshner, Vincent Vinciguerra, Electra Paskett
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 3942–3947.
Published: 01 December 1999
View article titled, Phase I Clinical Study of Fish Oil Fatty Acid Capsules for Patients with Cancer Cachexia: Cancer and Leukemia Group B Study 9473
Open the PDF for Phase I Clinical Study of Fish Oil Fatty Acid Capsules for Patients with Cancer Cachexia: Cancer and Leukemia Group B Study 9473 in another window